Cite
Martínez-Feito A, Navarro-Compán V, Hernández-Breijo B, et al. Early monitoring of infliximab serum trough levels predicts long-term therapy failure in patients with axial spondyloarthritis. Scand J Rheumatol. 2021;1-8doi: 10.1080/03009742.2021.1914430.
Martínez-Feito, A., Navarro-Compán, V., Hernández-Breijo, B., Olariaga-Mérida, E., Peiteado, D., Villalba, A., Nuño, L., Monjo, I., Diego, C., Pascual-Salcedo, D., Nozal, P., Balsa, A., & Plasencia-Rodríguez, C. (2021). Early monitoring of infliximab serum trough levels predicts long-term therapy failure in patients with axial spondyloarthritis. Scandinavian journal of rheumatology, 1-8. https://doi.org/10.1080/03009742.2021.1914430
Martínez-Feito, A, et al. "Early monitoring of infliximab serum trough levels predicts long-term therapy failure in patients with axial spondyloarthritis." Scandinavian journal of rheumatology vol. (2021): 1-8. doi: https://doi.org/10.1080/03009742.2021.1914430
Martínez-Feito A, Navarro-Compán V, Hernández-Breijo B, Olariaga-Mérida E, Peiteado D, Villalba A, Nuño L, Monjo I, Diego C, Pascual-Salcedo D, Nozal P, Balsa A, Plasencia-Rodríguez C. Early monitoring of infliximab serum trough levels predicts long-term therapy failure in patients with axial spondyloarthritis. Scand J Rheumatol. 2021 Jun 29;1-8. doi: 10.1080/03009742.2021.1914430. Epub 2021 Jun 29. PMID: 34182885.
Copy
Download .nbib
